Element List	Current Year	Previous Year	%Change
Sales/Revenue	61,351,419	61,333,831	0.03
Gross Profit (Loss)	16,588,809	17,584,110	-5.66
Operational Profit (Loss)	434,609	1,329,465	-67.31
Net profit (Loss)	175,867	685,968	-74.36
Total Comprehensive Income	252,468	674,033	-62.54
Total Shareholders Equity (after Deducting Minority Equity)	22,621,744	22,369,276	1.13
Profit (Loss) per Share	0.12	0.45
All figures are in (Actual) Saudi Arabia, Riyals

Element List	Amount	Percentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value	-	-
All figures are in (Actual) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year	Revenues: The company achieved a slight increase in revenues amounting to 17,588 Saudi riyals, or (0.028%), compared to the previous year 2023 AD.
The reason of the increase (decrease) in the net profit during the current year compared to the last year is	Net Profit: Net profit reached SAR 175,867 in 2024, a decrease of 74.4%. This decrease is attributed to the company's investment in promotional offers to support non-pharmaceutical product sales, and to the increase in sales and distribution expenses for new branches that are growing to achieve the sales target.
Statement of the type of external auditor's report	Unmodified opinion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion)	nothing
Reclassification of Comparison Items	Certain comparative figures have been reclassified to conform to the presentation of the current year's financial statements.
Additional Information	-